Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[Amatuer17]

This is the big gamble - Celebrex generic is already in market - so who will really be interested in going against generics with known thin margins?

So chance of immediate collaboration or BO is low - KTOV is so small that they cannot market the product.

One possibility I see is - TEVA already has approval to sell generic Celebrex in US since 2014 - they may like to buy this product license and combine as a variant of Celebrex for sub-population. This and Israeli connection can help KTOV to cut a deal - however with Teva’s problems - not sure we can expect any significant deal.

The co market cap is $28 million - so Teva can buy them out at just 56 to $84 million (really cheap) to take out competition. That will give 2 to 2.5 times current price - I will be more than happy to come out at that price.

Do not see much potential for appreciation